ProQR Therapeutics (PRQR) Liabilities and Shareholders Equity (2012 - 2026)

ProQR Therapeutics has reported Liabilities and Shareholders Equity for 15 years, with the latest figure at $115.9 million in Q1 2026.

• Quarterly Liabilities and Shareholders Equity fell 27.34% year-over-year to $115.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $548.3 million (down 6.04% YoY) and the FY2025 annual result came in at $131.3 million, down 26.87% from the prior year.
• Liabilities and Shareholders Equity declined to $115.9 million in Q1 2026 per PRQR's latest filing, from $131.3 million in the prior quarter.
• Over five years, Liabilities and Shareholders Equity peaked at $213.5 million in Q1 2022 and troughed at $115.9 million in Q1 2026.
• A 5-year average of $153.1 million and a median of $154.6 million in 2023 frame the typical range for Liabilities and Shareholders Equity.
• The sharpest annual moves came in 2022 and 2023: Liabilities and Shareholders Equity plunged 99.81% in 2022, then rose 25.97% in 2023.
• Over 5 years, Liabilities and Shareholders Equity stood at $174.8 million in 2022, then retreated by 15.12% to $148.4 million in 2023, then advanced by 20.98% to $179.5 million in 2024, then retreated by 26.87% to $131.3 million in 2025, then decreased by 11.66% to $115.9 million in 2026.
• According to Business Quant data, Liabilities and Shareholders Equity over the past three periods registered $115.9 million, $131.3 million, and $145.4 million for Q1 2026, Q4 2025, and Q3 2025 respectively.